🇺🇸 FDA

Intelligence Platform

Patents

Browse 912 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11660325

Compositions and methods of targeting cancer stem cells

The Board of Regents of the University of Texas System · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11660318

Use of adipose tissue-derived stromal stem cells in treating fistula

Takeda Pharmaceutical Company Limited · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11642401

Activation of resident memory T cells for cancer immunotherapy

Regents of the University of Minnesota · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11631483

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. · Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11629334

Methods of isolating T cells and T cell receptors having antigenic specificity for a cance

THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11622977

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11613735

Methods for reprograming non-hepatocyte cells into hepatocyte cells

BeiHao Stem Cell and Regenerative Medicine Translational Research Institute · Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11613754

Toxic RNAi active seed sequences for killing cancer cells

Northwestern University · Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11613739

Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) p

REGENXBIO INC. · Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11591622

Method of making and using mammalian liver cells for treating hemophilia or lysosomal stor

Sangamo Therapeutics, Inc. · Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11591381

Gene-edited natural killer cells

CRISPR THERAPEUTICS AG · Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11583556

Modified cells and methods of therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11583557

Placenta-derived multipotent stem cells

The Regents of the University of California · Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11578309

Universal donor cells

CRISPR THERAPEUTICS AG · Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11571445

Genetically engineered hematopoietic stem cells and uses thereof

Vor Biopharma Inc. · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11572541

Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treat

Providence Health & Services—Oregon · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11566230

Universal donor cells

CRISPR THERAPEUTICS AG · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11566228

Hemangio-colony forming cells

Astellas Institute for Regenerative Medicine · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11566242

Methods and compositions for reprogramming cells

The Regents of the University of Colorado, a Body Corporate · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559551

Genetically engineered hematopoietic stem cells and uses thereof

Vor Biopharma Inc. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11555057

Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor

The Regents of the University of California · Granted Tue Jan 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11504402

Compositions comprising bacterially derived minicells and methods of using the same

EnGeneIC Molecular Delivery Pty Ltd · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11497773

Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved func

CRISPR THERAPEUTICS AG · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485976

Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same

EnGeneIC Molecular Delivery Pty Ltd · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted